Phase II trial of vinorelbine in 120-hours continuous infusion in metastatic breast cancer refractory to anthracyclines

被引：0
|
作者：
Jara, C
Alonso, C
Fernandez, A
GomezAldaravi, L
Arroyo, M
Bosch, C
Tres, A
Gonzalez, M
机构：
[1] HOSP LA PAZ,MADRID,SPAIN
[2] HOSP CLIN,ZARAGOZA,SPAIN
[3] GEN HOSP,SECC ONCOL MED,ALBACETE,SPAIN
来源：
EUROPEAN JOURNAL OF CANCER | 1997年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：706 / 706
页数：1
相关论文
共 50 条
  • [41] Phase II study of vinorelbine, epirubicin and continuous 5-fluorouracil infusion as first line treatment in anthracycline naive metastatic breast cancer.
    Berruti, A
    Bitossi, R
    Gorzegno, G
    Donadio, M
    Nigro, C
    Ardine, M
    Bertetto, O
    Bottini, A
    Danese, S
    Bertone, E
    Sarobba, MG
    Farris, A
    Bellino, R
    Katsaros, D
    Castiglione, F
    Grassi, L
    Marinone, C
    Dogliotti, L
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S91 - S91
  • [42] Phase II study with the combination of capecitabine (C) and vinorelbine (V) in metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes.
    Estevez, LG
    Batista, N
    Sánchez-Rovira, P
    Velasco, A
    Domine, M
    Lobo, F
    Oramas, J
    Cruz, J
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 63S - 63S
  • [43] Treatment of refractory metastatic breast cancer with 5-fluorouracil plus levofolinic acid as continuous venous infusion: A phase II study
    Gebbia, V
    Borsellino, N
    Testa, A
    Tirrito, M
    Varvara, F
    Cucchiara, A
    Mauceri, G
    Girlando, A
    Ferrara, M
    Caruso, F
    ANTICANCER RESEARCH, 1999, 19 (4C) : 3553 - 3557
  • [44] A multicentric phase II study with vinorelbine and protracted fluorouracil infusion for advanced breast cancer patients previously treated with anthracyclines and/or taxanes. Is salvage chemotherapy for metastatic breast cancer always effective and well tolerated?
    Kanaev, S
    Novikov, S
    Jukova, L
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S70 - S70
  • [45] Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes:: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial
    Martin, Miguel
    Ruiz, Amparo
    Munoz, Monserrat
    Balil, Ana
    Garcia-Mata, Jesus
    Calvo, Lourdes
    Carrasco, Eva
    Mahillo, Esther
    Casado, Antonio
    Angel Garcia-Saenz, Jose
    Jose Escudero, M.
    Guillem, Vicente
    Jara, Carlos
    Ribelles, Nuria
    Salas, Fernando
    Soto, Celia
    Morales-Vasquez, Flavia
    Rodriguez, Cesar A.
    Adrover, Encarna
    Ramon Mel, Jose
    LANCET ONCOLOGY, 2007, 8 (03): : 219 - 225
  • [46] Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer
    G. Mariani
    P. Tagliabue
    P. Zucchinelli
    C. Brambilla
    R. Demicheli
    E. Villa
    A. Marchianò
    P. Valagussa
    G. Bonadonna
    L. Gianni
    Breast Cancer Research and Treatment, 2001, 70 : 163 - 169
  • [47] Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer
    Mariani, G
    Tagliabue, P
    Zucchinelli, P
    Brambilla, C
    Demicheli, R
    Villa, E
    Marchianò, A
    Valagussa, P
    Bonadonna, G
    Gianni, L
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 70 (03) : 163 - 169
  • [48] Phase II study of vinorelbine and ifosfamide in anthtracycline resistent metastatic breast cancer
    Pronzato, P
    Queirolo, P
    Landucci, M
    Vaira, F
    Vigani, A
    Gipponi, M
    Cafiero, F
    BREAST CANCER RESEARCH AND TREATMENT, 1997, 42 (02) : 183 - 186
  • [49] Phase II study of vinorelbine and ifosfamide in anthtracycline resistent metastatic breast cancer
    P. Pronzato
    P. Queirolo
    M. Landucci
    F. Vaira
    A. Vigani
    M. Gipponi
    F. Cafiero
    Breast Cancer Research and Treatment, 1997, 42 : 183 - 186
  • [50] Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer
    Park, In Hae
    Ro, Jungsil
    Lee, Keun Seok
    Kim, Shi Nae
    Yun, Young Ho
    Nam, Byung Ho
    INVESTIGATIONAL NEW DRUGS, 2010, 28 (05) : 659 - 669
12345